Nov 24, 2015 - and clinical data are necessary to assess comparative effectiveness as early in the drug ... generally we
Mar 23, 2017 - The Role of the Pharmacist in Raising Patient Awareness. Mike Isles. Executive Director, European Allianc
There was a problem previewing this document. Retrying... Download. Connect more apps... Try one of the apps below to op
key medicines available at health facilities (see, for example, ...... WHO/EDM (World Health Organization/Essential Drugs and ...... edm-country-profiles.html).
Committee on Medicines, a committee of the Royal College of Paediatrics and Child. Health and the Neonatal and Paediatri
Sep 29, 2014 - Partnership (TTIP), a free-trade agreement (FTA) that could ..... criticism from civil society and a wide
Jul 2, 2013 - Table 5.3 Comparison of the PBS reimbursement status of oncology ...... The HREC in each host institution/
to highlight issues of access to medicines and health-related technologies, which ... Member states should explore and p
Sep 29, 2014 - How the European trade agenda continues to undermine access to medicines. Insufficient ...... American Un
pocket 2. Those affected by these high costs are disproportionately poor and medicines .... exported from PubMed as text
As a leading global health care company, Johnson & Johnson has an important ... General Access to Medicine Managemen
lung cancer but in Lillian's case her much rarer mutation is in the ROS1 gene. ...... of train track staples up the back
including doctors, nurses, pharmacists and pharmacist's .... Pharmacist's assistants, nurses Health facility budget therefore ...... Convenient online submission.
355(c)(3)(E)(ii) (1984). 5 Directive ..... ing from the pharmaceutical industry.47 The CSDD's most ... 48 Tufts Center for the Study of Drug Development (CSDD).
Mar 23, 2017 - Access to Unlicensed Medicines;. Right Medicine, Right Patient, Right Time. This satellite symposium is o
Symposium Invitation
Symposium Agenda Access to Unlicensed Medicines; Right Medicine, Right Patient, Right Time Regardless of whether the need for accessing unlicensed medicines is driven by a supply disruption, treatment of a rare disease or other options being unsuitable or simply not working, the role of hospital pharmacists is critical in ensuring patient treatment continues uninterrupted. Sourcing and timely supply of unlicensed medicines is complex and demanding. In this meeting, we will explore this changing landscape and give pointers on how best to respond to these challenges and maintain an optimal service for all stakeholders: patients, physicians and policy-makers. Come and join our symposium where you will learn from expert insights and opinions on this patient-critical and evolving issue.
OUR FOCUS is on giving healthcare professionals access to a world of unlicensed medicines
09:00 - 09:10
Chair’s Welcome Bernard Naughton
Doctoral Researcher, Keele University & University of Oxford Clinical Pharmacist, Oxford University Hospitals NHS Foundation Trust
09:10 - 09:30
A History of Access to Medicines; 30 Years On Ivo Timmermans Chief Medical Officer, Clinigen Group
Access to Unlicensed Medicines; Right Medicine, Right Patient, Right Time Thursday 23 March 2017 Théâtre Claude Debussy; 09:00 - 10:30 rd
Part of the Clinigen Group
www.clinigengroup.com/healthcare-professionals
09:30 - 09:50
Fulfilling Patient Needs; A View From The Sharp End Bernard Naughton
09:50 - 10:10
Falsified Medicines; The Role of the Pharmacist in Raising Patient Awareness Mike Isles
Executive Director, European Alliance for Access to Safe Medicines
10:10 - 10:25
Q&A Panel
10:25 - 10:30
Chair’s Summary Bernard Naughton
This satellite symposium is organised by Idis Global Access
